MEIP vs. LPTX, UNCY, PTN, CRVS, VTGN, ORGS, ELDN, YMTX, TXMD, and CKPT
Should you be buying MEI Pharma stock or one of its competitors? The main competitors of MEI Pharma include Leap Therapeutics (LPTX), Unicycive Therapeutics (UNCY), Palatin Technologies (PTN), Corvus Pharmaceuticals (CRVS), VistaGen Therapeutics (VTGN), Orgenesis (ORGS), Eledon Pharmaceuticals (ELDN), Yumanity Therapeutics (YMTX), TherapeuticsMD (TXMD), and Checkpoint Therapeutics (CKPT). These companies are all part of the "pharmaceutical preparations" industry.
MEI Pharma vs.
MEI Pharma (NASDAQ:MEIP) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.
MEI Pharma received 85 more outperform votes than Leap Therapeutics when rated by MarketBeat users. However, 68.52% of users gave Leap Therapeutics an outperform vote while only 64.67% of users gave MEI Pharma an outperform vote.
Leap Therapeutics has a net margin of 0.00% compared to MEI Pharma's net margin of -49.80%. Leap Therapeutics' return on equity of -65.01% beat MEI Pharma's return on equity.
In the previous week, Leap Therapeutics had 5 more articles in the media than MEI Pharma. MarketBeat recorded 9 mentions for Leap Therapeutics and 4 mentions for MEI Pharma. MEI Pharma's average media sentiment score of 0.22 beat Leap Therapeutics' score of 0.03 indicating that MEI Pharma is being referred to more favorably in the media.
MEI Pharma has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500.
35.7% of MEI Pharma shares are owned by institutional investors. Comparatively, 37.4% of Leap Therapeutics shares are owned by institutional investors. 6.2% of MEI Pharma shares are owned by insiders. Comparatively, 12.5% of Leap Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
MEI Pharma has higher revenue and earnings than Leap Therapeutics. MEI Pharma is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks.
MEI Pharma presently has a consensus target price of $3.00, indicating a potential upside of 1,220.42%. Leap Therapeutics has a consensus target price of $2.80, indicating a potential upside of 803.23%. Given MEI Pharma's higher possible upside, equities analysts plainly believe MEI Pharma is more favorable than Leap Therapeutics.
Summary
Leap Therapeutics beats MEI Pharma on 10 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MEIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MEI Pharma Competitors List
